Emerging biologic targets in type 2 and non-type 2 asthma

Many patients have benefited tremendously from the currently available asthma biologics in achieving better symptoms control, improved quality of life, and reduced cumulative dose of systemic steroids. Despite this, most patients are unable to achieve remission, potentially related to shortcomings of these therapies in addressing asthma's heterogeneous pathophysiology. As such, a variety of novel therapeutic mechanisms and targets are being investigated and are discussed in this review.